Skip to content

Intellia Therapeutics, Inc.

Intellia researchers work tirelessly to harness the genome editing technology CRISPR/Cas9 for human therapeutic use. Their mission is to develop curative genome editing treatments that can positively transform the lives of people living with severe and life-threatening diseases. As a leader in this space, they take this responsibility to patients seriously.

Intellia are employing a modular genome editing platform to create diverse in vivo and ex vivopipelines, spanning a range of therapeutic indications. Guided by this full-spectrum approach, they are committed to making CRISPR/Cas9-based medicines a reality for patients suffering from genetic diseases and to creating novel engineered cell therapies for various cancers and autoimmune diseases.

More information about Intellia’s data protection policies may be found by clicking here. is Intellia’s company website, and will open in a new browser tab.

Kaleidoscope Data Privacy Consultants Limited (KDPC IE) is the EEA Data Protection Representative for the purposes of the General Data Protection Regulation (GDPR) for Intellia through our office in Dublin.

If you have a question about how your personal data is processed, please select your preferred language from the menu on the left. You will find details on how to contact Kaleidoscope Data Privacy Consultants Limited (KDPC IE) including a form to request a telephone call or submit your question online.

Contact details of our office in Dublin:

Kaleidoscope Data Privacy Consultants Limited, The Black Church, St Mary’s Place, Dublin D07 P4AX

+353 (0) 153 14430 (Note: calls are answered in English. If you are not comfortable with English, please fill out the contact form and we will call you and speak in the language of your choice through an interpreter.)